On April 7, 2026, Insmed Inc. reported topline efficacy results from its Phase 2b CEDAR study of brensocatib in patients with hidradenitis suppurativa, showing a 45.5% reduction in abscess count for the 10 mg dose compared to 57.1% for placebo. The company will discontinue brensocatib's development for this condition and plans to share further data at a future congress.